GlaxoSmithKline

Seven pharma companies offer deprioritized compounds for re-purposing

Wednesday, July 23, 2014 10:15 AM

U.K. researchers will be granted access to a ‘virtual library’ of deprioritized pharmaceutical compounds through a new partnership between the Medical Research Council (MRC) and seven global drug companies.

More... »

WIRB Copernicus Group

EFPIA launches IMI2—a $4.5B public-private healthcare partnership

Wednesday, July 9, 2014 12:09 PM

EFPIA has announced the launch of IMI2, the continuation of the successful partnership of industry and public bodies to tackle health needs. IMI is a public-private partnership (PPP) between the European Commission and EFPIA, the European Federation of Pharmaceutical Industries and Associations. The first phase of IMI (2008 to 2013) was established with a budget of $2.7 billion. IMI2 has been established under the E.U. framework program Horizon 2020 with an even bigger budget of $4.5 billion—bringing together the public and private sectors in the largest healthcare PPP in Europe.

More... »


Medical Research Council launches U.K. Dementias Research Platform

Thursday, June 19, 2014 01:39 PM

The Medical Research Council (MRC) has launched the U.K. Dementias Research Platform (UKDP), a $27.2 million public-private partnership set up to speed up research into dementias. The collaboration aims to enable earlier detection, improved treatment and, ultimately, prevention of the disease by looking not just at what is going wrong in the brain, but at the brain in the context of the whole body.

More... »

Privacy Analytics launches clinical trials data-sharing solution

Wednesday, June 18, 2014 12:51 PM

Privacy Analytics, a provider of data anonymization solutions for the healthcare industry, has launched a new solution to enable pharma companies to share clinical trials data while protecting the privacy of individual participants. The new offering accelerates the ability of pharma companies to meet increasing requests for individual-level participant data and clinical study reports by academic institutions, patients and other third parties.

More... »

Adaptimmune, GlaxoSmithKline collaborate on cancer therapies

Tuesday, June 3, 2014 08:05 AM

Adaptimmune, a biotechnology company developing TCR engineered T-cells to treat cancer, has entered into a strategic collaboration and licensing agreement with GlaxoSmithKline (GSK) for the development and commercialization of its lead clinical cancer program.

More... »

Jack Modell joins Rho as senior medical officer

Thursday, May 22, 2014 11:15 AM

Rho, a privately held CRO located in Chapel Hill, N.C., has announced that Dr. Jack Modell joined its team as senior medical officer, bringing 20 years of experience in clinical research, teaching and patient care in academic medicine, and an additional 10 years of experience in clinical drug development (phase II-IV), medical affairs, medical governance, drug safety and management within the pharmaceutical industry. 

More... »

Despite fewer healthcare deals, corporate venture capital booming

Friday, May 16, 2014 12:39 PM

While last year’s boom in corporate venture capital financing continues to expand in some business sectors, the healthcare space raised only $288 million in 23 deals in the first quarter of 2014—the lowest in five quarters.

More... »

Pernix to acquire Treximet migraine tablets from GlaxoSmithKline

Thursday, May 15, 2014 11:23 AM

Pernix Therapeutics, a specialty pharmaceutical company, has signed an agreement with GlaxoSmithKline to acquire the U.S. rights to Treximet (sumatriptan / naproxen sodium) for the acute treatment of migraine attacks with or without aura in adults.

More... »

Theravance to split into two companies: R&D and royalty management

Thursday, May 8, 2014 01:21 PM

Biopharmaceutical company Theravance has announced it will split into two independent, publicly traded companies via a stock dividend on May 15.

More... »

Pfizer pursues AstraZeneca for potential $100 billion acquisition deal

Monday, April 28, 2014 02:15 PM

Having rejected two bids since January, Pfizer made its next move on Monday—a $99 billion stock and cash offer to acquire AstraZeneca, to create a single U.K.-based company that would become the world’s largest pharmaceutical company.

More... »

CenterWatch Data Library
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

August 18

Ebola outbreak highlights need to improve biosafety, infrastructure to handle future health emergencies

More African American professional women open to participating in medical research

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

August

Reality of costs and impact rain on Sunshine Act
Concerns mount over compliance burden on CROs, sponsors, unanticipated consequences for research

Cloud computing expanding into all areas of clinical trial conduct
Benefits outweigh the complexities, challenges of finding right vendors

Already a subscriber?
Log in to your digital subscription.

Purchase the August issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

July

IRB market consolidating rapidly
Private equity driving a new commercial ethical review landscape

Lessons learned from medical device trials
Smaller, faster, more flexible trials hold important insights for pharmaceutical innovation

Already a subscriber?
Log in to your digital subscription.

Purchase the July issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs